Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31462263 | 0.98 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL15224106 | 0.89 | SIGMAR1 (0.69) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6681439 | 0.85 | ALDH1A1 (0.83) | ALDH1A1SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL5064043 | 0.85 | ALDH1A1 (0.71) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL15224158 | 0.84 | SIGMAR1 (0.73) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL15224104 | 0.84 | FAAH (0.60) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL8900932 | 0.84 | SIGMAR1 (0.83) | SIGMAR1KMT2AMEN1POLBFAAH | |
| SCHEMBL2841801 | 0.83 | ALDH1A1 (0.68) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL5247018 | 0.83 | FAAH (0.63) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL3222136 | 0.83 | ALDH1A1 (0.66) | SIGMAR1ALDH1A1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | disclosed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | SIGMAR1 561/4885ALDH1A1 2252/4885SMN1; SMN2 2355/4885 |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | SIGMAR1 1323/4885ALDH1A1 390/4885SMN1; SMN2 4373/4885 |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | SIGMAR1 1936/4885ALDH1A1 3332/4885SMN1; SMN2 4665/4885 |
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | SIGMAR1 3069/4885ALDH1A1 230/4885SMN1; SMN2 2521/4885 |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | SIGMAR1 3744/4885ALDH1A1 1010/4885SMN1; SMN2 2873/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | SIGMAR1 1062/4885ALDH1A1 1225/4885SMN1; SMN2 709/4885 |
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | CCR8, RPS8, HDHD5 | SIGMAR1 563/4885ALDH1A1 3354/4885SMN1; SMN2 4371/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | SIGMAR1 1062/4885ALDH1A1 1225/4885SMN1; SMN2 709/4885 |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | SIGMAR1 3069/4885ALDH1A1 230/4885SMN1; SMN2 2521/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | SIGMAR1 609/4885ALDH1A1 2087/4885SMN1; SMN2 2374/4885 |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | NOX1, NOX4, CYBB | SIGMAR1 3069/4885ALDH1A1 230/4885SMN1; SMN2 2521/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | SIGMAR1 1062/4885ALDH1A1 1225/4885SMN1; SMN2 709/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | SIGMAR1 1936/4885ALDH1A1 3332/4885SMN1; SMN2 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.